GASTROMARK
LOE Approachingferumoxsil
NDAORALSUSPENSION
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GASTROMARK (ferumoxsil) is an oral suspension containing ferumoxsil, an iron oxide-based contrast agent used for gastrointestinal imaging. It enhances visualization of the bowel during MRI and CT scans by providing negative contrast in the stomach and small intestine. The product targets patients undergoing diagnostic imaging procedures requiring improved bowel delineation.
LOE Approaching
With LOE approaching and minimal ongoing commercial support, career growth on this brand is limited; team size likely contracting or stable in maintenance mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GASTROMARK represents a legacy diagnostic product with minimal current hiring activity (0 linked jobs) and limited career advancement potential. Working on this product offers stable but low-growth experience, best suited for professionals managing mature portfolios or transitioning diagnostic franchises.
Product ManagerSales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.